Abstract
Short Call Abstracts
Highlights
Treatments are limited for pts with RADIOACTIVE IODINE (RAI)-refractory differentiated thyroid cancer (DTC) that is resistant to VEGFR-targeted therapy
In the present preclinical studies, we evaluated the efficacy of a novel bromodomain and extra-terminal domain (BET) inhibitor, PLX51107 (PLX), currently in clinical trials for other solid tumors and hematologic malignancies, singly or with a MEK inhibitor, PD0325901(PD) in the treatment of Anaplastic thyroid cancer (ATC)
We examined the effects of PLX, PD, or their combination on the mouse xenograft tumor development of human ATC cell lines (THJ-11T and THJ-16T), each having been authenticated by DNA short tandem repeat analysis
Summary
ISO-MYOSMINE, A NOVEL IMMUNOMETABOLIC REGULATOR, REDUCES THE INCIDENCE AND SEVERITY OF THYROIDITIS IN THE NOD.H-2H4 MOUSE MODEL G. Iso-myosmine is a synthetic derivative of myosmine, a member of the tobacco alkaloids. These compounds are endowed with immunoregulatory properties and support the epidemiological observations that smoking reduces the odds of developing thyroid antibodies and hypothyroidism. To assess the effect and mechanism(s) of action of iso-myosmine, we chose the NOD.H-2h4 mouse model where thyroiditis develops spontaneously and is accelerated by iodine administration. The number of CD3 T cells and CD19 B cells infiltrating the thyroid gland (which increased as expected in the iodine group), was markedly dampened by iso-myosmine, as assessed by flow cytometry. Extending to other autoimmune diseases, will confirm the potential clinical utility of iso-myosmine as a novel immunometabolic regulator
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
